These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38819948)

  • 41. The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: a validation study.
    Saraiva L; Cunha RN; Jesus D; Gatto M; Zen M; Iaccarino L; da Silva JAP; Doria A; Inês LS
    Rheumatology (Oxford); 2024 Apr; 63(4):1123-1129. PubMed ID: 37458482
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus.
    Uribe AG; Vilá LM; McGwin G; Sanchez ML; Reveille JD; Alarcón GS
    J Rheumatol; 2004 Oct; 31(10):1934-40. PubMed ID: 15468356
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Belimumab in the treatment of Portuguese Systemic Lupus Erythematosus patients: a real-life multicenter study.
    Fernandes BM; Barreira S; Fonseca JE; Cunha M; Santos MJ; Gonçalves N; Fernandes AL; Rodrigues J; Fontes T; Costa L; Bernardes M
    Acta Reumatol Port; 2020; 45(3):170-176. PubMed ID: 33139681
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study.
    Hunnicutt JN; Fairburn-Beech J; Georgiou ME; Richards A; Gregan YI; Quasny H; Chauhan D
    Lupus Sci Med; 2022 Nov; 9(1):. PubMed ID: 36450407
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in Argentina.
    Babini A; Cappuccio AM; Caprarulo C; Casado G; Eimon A; Figueredo H; García MA; Magri S; Mannucci P; Perez Rodriguez S; Pons-Estel BA; Velozo EJ; Iglesias-Rodriguez M; Streger G
    Lupus; 2020 Oct; 29(11):1385-1396. PubMed ID: 32791930
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased risk of hospital admissions in patients with active systemic lupus erythematosus (SLE) classified according to two different SLE disease activity indices: a prospective cohort study.
    Lu MC; Hsu CW; Koo M; Lai NS
    Clin Exp Rheumatol; 2023 Jul; 41(7):1409-1416. PubMed ID: 36377575
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Performance of systemic lupus erythematosus responder index for detecting clinician-rated responders in patients with active systemic lupus erythematosus.
    Leosuthamas P; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
    Int J Rheum Dis; 2023 Apr; 26(4):667-672. PubMed ID: 36802112
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme.
    Maslen T; Bruce IN; D'Cruz D; Ianosev M; Bass DL; Wilkinson C; Roth DA
    Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33568389
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment pathways in an inception lupus cohort over the first three years.
    Hanly JG; Sayani A; Doucette S; Iczkovitz S; Terres JAR
    Lupus; 2017 Feb; 26(2):119-124. PubMed ID: 27365369
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comprehensive disease control in systemic lupus erythematosus.
    Ceccarelli F; Olivieri G; Sortino A; Dominici L; Arefayne F; Celia AI; Cipriano E; Garufi C; Lapucci M; Mancuso S; Natalucci F; Orefice V; Perricone C; Pirone C; Pacucci VA; Spinelli FR; Truglia S; Alessandri C; Sciandrone M; Conti F
    Semin Arthritis Rheum; 2021 Apr; 51(2):404-408. PubMed ID: 33652293
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort.
    Saccon F; Zen M; Gatto M; Margiotta DPE; Afeltra A; Ceccarelli F; Conti F; Bortoluzzi A; Govoni M; Frontini G; Moroni G; Dall'Ara F; Tincani A; Signorini V; Mosca M; Frigo AC; Iaccarino L; Doria A
    Ann Rheum Dis; 2020 Jul; 79(7):943-950. PubMed ID: 32321721
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N
    RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Belimumab for systemic lupus erythematosus.
    Singh JA; Shah NP; Mudano AS
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD010668. PubMed ID: 33631841
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
.
    Sheikh SZ; Hammer AE; Fox NL; Groark J; Struemper H; Roth D; Gordon D
    Int J Clin Pharmacol Ther; 2016 Nov; 54(11):914-922. PubMed ID: 27668697
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sensitivity analyses of four systemic lupus erythematosus disease activity indices in predicting the treatment changes in consecutive visits: a longitudinal study.
    Fatemi A; Raeisi A; Sayedbonakdar Z; Smiley A
    Clin Rheumatol; 2018 Apr; 37(4):955-962. PubMed ID: 29256112
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study.
    Zen M; Bassi N; Nalotto L; Canova M; Bettio S; Gatto M; Ghirardello A; Iaccarino L; Punzi L; Doria A
    Clin Exp Rheumatol; 2012; 30(6):856-63. PubMed ID: 22765883
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Performance of a New Instrument for the Measurement of Systemic Lupus Erythematosus Disease Activity: The SLE-DAS.
    Koo M; Lu MC
    Medicina (Kaunas); 2023 Nov; 59(12):. PubMed ID: 38138199
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of belimumab in patients with systemic lupus erythematosus treated with low dose or no corticosteroids.
    Lee YJ; Ahn SM; Hong S; Oh JS; Lee CK; Yoo B; Kim YG
    Korean J Intern Med; 2024 Mar; 39(2):338-346. PubMed ID: 38031366
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
    Wallace DJ; Stohl W; Furie RA; Lisse JR; McKay JD; Merrill JT; Petri MA; Ginzler EM; Chatham WW; McCune WJ; Fernandez V; Chevrier MR; Zhong ZJ; Freimuth WW
    Arthritis Rheum; 2009 Sep; 61(9):1168-78. PubMed ID: 19714604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.